Previous Page
28
nanotimes
Companies Facts
sales were $705.6 million, a 16.5% gain over last year. Sales in local currency increased 11.9%, orders in local currency increased 11.0%. Diluted earnings per share (“EPS”) were $0.59, compared to $0.61 last year.
icosun Oy, Finland-based global manufacturer of state-of-the-art Atomic Layer Deposition (ALD)
equipment, has successfully scaled up several new, important ALD processes. Of compound materials, various new sulfides, e.g. Gd2
O2 S (based on the
process originally developed by Prof. Mikko Ritala’s group at University of Helsinki, Finland), indium sul- fide and zinc sulfide, and oxides, e.g. antimony oxide and Al2
O3 /Ta2 O5 nanolaminates and mixed oxides
(also at lower temperatures), are now available for industrial scale processes. Of metals, gold, copper, silver and ruthenium, and of metallic compound ma- terials, TiAlCN and TiN, have also been successfully deposited by novel ALD processes on industrial scale wafer sizes.
Picosun’s SUNALE™ ALD tools are chosen for pro- duction by various industries across four continents. Picosun Oy is a part of Stephen Industries Inc. Oy.
Sivida Corp. (NASDAQ: PSDV; ASX:PVA) has signed a funded technology evaluation agree-
ment with a leading global pharmaceutical company to evaluate pSivida’s bioerodible Durasert™ drug delivery technology in ophthalmology. pSivida is also
Q
ualcomm MEMS Technologies, Inc. (QMT) a wholly owned subsidiary of Qualcomm In-
corporated (NASDAQ: QCOM), and Kyobo Book Centre, Korea’s largest seller of books, announced the retail availability of the world’s first e-reader to include mirasol®
display technology.
The Kyobo e-Reader features a 5.7” XGA format (1024 x 768 pixels) mirasol display (screen resolution of 223 ppi) and Qualcomm’s 1.0 GHz Snapdragon™ S2 class processor. Kyobo’s custom application inter- face sits atop an Android 2.3 base. Kyobo’s e-Reader is now available for purchase at the full retail price of KRW349,000 (US$310).
http://www.mirasoldisplays.com S for VivaGel®
tarpharma (ASX: SPL; OCTQX: SPHRY) announced that the Phase 3 clinical trial program bacterial vaginosis (BV) treatment has
now also been agreed with the European Medicines Agency (EMA). This European scientific advice is in addition to the agreement recently reached with the US Food and Drug Administration (FDA) announced by the Company on October 10, 2011.
Starpharma recently presented to the EMA the proposed design of Phase 3 studies and associated
independently developing a product to treat uveitis affecting the posterior segment of the eye (posterior uveitis) and a product to treat glaucoma and ocular hypertension in collaboration with Pfizer.
11-11/12 :: November/December 2011